Beckman Coulter, Inc. recalls Access Erythropoietin (EPO)
- Published
- 12 Mar 2025
- Units affected
- 498 US; 1576 OUS
- Agency
- FDA
- Country
- United States
The hazard
Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Contact your doctor, clinic or the device maker to find out if your device is affected and what to do next. Do not stop using a life-supporting device without medical advice.
- Check the model and lot or serial number on the device label.
- Speak to your doctor or the clinic that supplied the device before stopping use.
Product details
Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells.
- Brand / company
- Beckman Coulter, Inc.
- Codes / lots
- Catalog A16364 UDI-DI 15099590201838 Lot 439363
- Distribution
- Domestic distribution to AL AR AZ CA CT FL ID IL IN KS MA MI NC NE NJ NY OH OR PA TN TX UT WA WV. International distribution to Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Philippines, Russian Federation, Saudi Arabia, Slovakia, Spain, United Kingdom of Great Britain and Northern Ireland
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 12 Mar 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.